PTTG2 抗体 (AA 56-84)
(1 reference)-
- 抗原 See all PTTG2 products
- PTTG2 (Pituitary Tumor-Transforming 2 (PTTG2))
-
抗原表位
- AA 56-84
-
适用
- 人
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This PTTG2 antibody is un-conjugated
-
应用范围
- Western Blotting (WB), Immunofluorescence (IF)
- 纯化方法
- This antibody is purified through a protein A column, followed by peptide affinity purification.
- 免疫原
- This PTTG2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 56-84 amino acids from the Central region of human PTTG2.
- 克隆位点
- RB35901
- 亚型
- Ig Fraction
-
anti-Pituitary Tumor-Transforming 2 (PTTG2) (AA 1-191) antibody
PTTG2 适用: 人 WB, IF 宿主: 兔 Polyclonal unconjugated
anti-Pituitary Tumor-Transforming 2 (PTTG2) (AA 2-174) antibodyPTTG2 适用: 人 WB, IHC (p), IHC 宿主: 兔 Polyclonal unconjugated
anti-Pituitary Tumor-Transforming 2 (PTTG2) (AA 1-202) antibodyPTTG2 适用: 人 ELISA, IF 宿主: 兔 Polyclonal unconjugated
anti-Pituitary Tumor-Transforming 2 (PTTG2) (AA 1-191) antibodyPTTG2 适用: 人 WB 宿主: 小鼠 Polyclonal unconjugated
anti-Pituitary Tumor-Transforming 2 (PTTG2) (AA 51-100) antibodyPTTG2 适用: 人, 小鼠 WB 宿主: 兔 Polyclonal unconjugated
anti-Pituitary Tumor-Transforming 2 (PTTG2) (Middle Region) antibodyPTTG2 适用: 人, 小鼠, Cow, 犬, Pig WB 宿主: 兔 Polyclonal unconjugated
-
- 应用备注
- IF: 1:10~50. WB: 1:2000. WB: 1:1000
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 缓冲液
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C,-20 °C
- 储存方法
- PTTG2 Antibody (Center) can be refrigerated at 2-8 °C for up to 6 months. For long term storage, keep at -20 °C.
- 有效期
- 6 months
-
-
: "Pituitary tumor transforming gene PTTG2 induces psoriasis by regulating vimentin and E-cadherin expression." in: International journal of clinical and experimental pathology, Vol. 8, Issue 9, pp. 10887-93, (2016) (PubMed).
-
: "Pituitary tumor transforming gene PTTG2 induces psoriasis by regulating vimentin and E-cadherin expression." in: International journal of clinical and experimental pathology, Vol. 8, Issue 9, pp. 10887-93, (2016) (PubMed).
-
-
